BioCentury
ARTICLE | Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

October 14, 2013 7:00 AM UTC

BioDelivery Sciences International Inc. (NASDAQ:BDSI) was down $0.45 to $5.15 last week after FDA accepted for review an NDA for Bunavail buprenorphine naloxone to treat opioid dependence. The company expects a decision by early June 2014. The NDA was submitted under section 505(b)(2) of the Food, Drug and Cosmetic Act.

Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) was off $0.02 to $2.90 last week after saying FDA's Cardiovascular and Renal Drug Advisory Committee is tentatively scheduled to meet on Jan. 14 to discuss an NDA for Northera droxidopa to treat symptomatic neurogenic orthostatic hypotension (NOH). The PDUFA date is Feb. 14...